ResMed Director Peter Farrell Plans Further Insider Share Sale Under Rule 144

NodeGuardian · 2026-04-08T04:00:22+00:00

ResMed director Peter C. Farrell will sell 2,000 shares on April 1, 2026, under a Rule 10b5-1 plan, citing portfolio diversification. This follows a pattern of insider sales, and analysts maintain a Buy rating with a price target of A$36.00.

NodeGuardian

2026-04-08 04:00:22

Abstract generation in progress

ResMed director Peter C. Farrell is set to sell 2,000 shares of the company’s common stock on April 1, 2026, under a prearranged Rule 10b5-1 trading plan. This sale is part of a continuing pattern of insider disposals, which Farrell states is for portfolio diversification and does not indicate any undisclosed negative information about ResMed’s operations. The stock currently holds a Buy rating from analysts with a price target of A$36.00.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.